Ohr Pharmaceutical Announces Additional Positive Anatomic Data From the OHR-102 IMPACT Study Interim Analysis Presented at Annual Macula Society Meeting
March 02, 2015 07:30 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the presentation of new data from the IMPACT...
Ohr Pharmaceutical Appoints Avner Ingerman, M.D. as Chief Clinical Officer
February 26, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an Ophthalmology research and development company, today announced the appointment of Avner Ingerman, MD, to the...
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock
February 11, 2015 12:54 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it has closed its previously announced...
Ohr Pharmaceutical Reports Fiscal First Quarter 2015 Financial and Business Results
February 09, 2015 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its first fiscal quarter ended December...
Ohr Pharmaceutical to Present at the 17th Annual BIO CEO & Investor Conference and Leerink Global Healthcare Conference in New York
February 09, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive...
Ohr Pharmaceutical Prices $25,000,000 Public Offering of Common Stock
February 06, 2015 08:30 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 6, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced the pricing of its previously announced underwritten...
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock
February 05, 2015 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it intends to offer its common stock in an...
Ohr Pharmaceutical Appoints Jason Slakter, MD, Chief Medical Officer, to Board of Directors
January 08, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Jason Slakter, MD, Chief Medical Officer, has...
Ohr Pharmaceutical Reports Fiscal Year 2014 Financial and Business Results
December 22, 2014 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its fiscal year ended September 30,...
Ohr Pharmaceutical to Announce Fiscal 2014 Financial Results and Host Conference Call on Monday, December 22
December 19, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced that it will report its...